Fulgent Genetics (FLGT) Q1 2025 earnings summary

Executive summary

• Revenue grew to $73.5 million in Q1 2025, up 14–18% year-over-year, driven by gains in precision diagnostics, anatomic pathology, and biopharma services, with strong fundamentals expected for 2025.

• Non-GAAP income was $1.2 million ($0.04 per share); GAAP net loss was $11.5 million ($0.37 per share), an improvement from Q1 2024.

• Adjusted EBITDA loss was $2.9 million, improved from a $3.2 million loss in Q1 2024.

• Ended Q1 with $814.6 million in cash, cash equivalents, restricted cash, and marketable securities.

• Continued investment in digital pathology, AI, and therapeutic development, with FID-007 in phase II and FID-022 set to begin phase I trials.

Financial highlights

• Q1 2025 revenue was $73.5 million, up from $64.5 million in Q1 2024, with negligible COVID-19 testing revenue.

• Gross margin improved to 38.6–39% from 34–34.3% year-over-year; non-GAAP gross margin was 41%.

• Operating loss was $19.8 million, improved from $21.8 million in Q1 2024.

• Non-GAAP operating loss was $7.3 million, with a non-GAAP operating margin of -9.9%.

• Stock repurchases totaled 0.5–0.52 million shares for $7.9–$8.7 million in Q1 2025; $139.6–$141.8 million remains authorized.

Outlook and guidance

• 2025 core revenue expected to be $310 million, a 10% year-over-year increase.

• Full-year non-GAAP gross margins expected to slightly exceed 40%.

• Non-GAAP operating margins projected at minus 15% for 2025.

• GAAP EPS loss expected to be $1.95 per share; non-GAAP loss of $0.65 per share for 2025.

• Anticipated year-end 2025 cash position of $770 million.